Evidence map›Paper›PMID 34988250›Full record

ArticleOpen forum infectious diseases2022

In-depth Characterization of Vaccine Breakthrough Infections With SARS-CoV-2 Among Health Care Workers in a Dutch Academic Medical Center.

Lidewij W Rümke, Femke C Groenveld, Yvonne M G van Os, Patrique Praest, Anniek A N Tanja, Dorien T C M de Jong, Jori Symons, Rob Schuurman, Tessa Reinders, L Marije Hofstra and 7 more

Open access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Malaria Genomics, Vaccine Development, and Microbiome.Pathogens (Basel, Switzerland) · 2023
    Review
  3. Review
  4. Observational
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Lidewij W RümkeVirology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands.
Femke C GroenveldVirology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands.
Yvonne M G van OsOccupational Health Office, Department of Human Resources, University Medical Center Utrecht, Utrecht, the Netherlands.
Patrique PraestVirology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands.
Anniek A N TanjaVirology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands.
Dorien T C M de JongVirology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands.
Jori SymonsVirology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands.
Rob SchuurmanVirology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands.
Tessa ReindersVirology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands.
L Marije HofstraVirology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands.
Stefan NierkensCenter for Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands.
Steven F T ThijsenDepartment of Medical Microbiology & Immunology, Utrecht, the Netherlands.
Michiel HeronDepartment of Medical Microbiology & Immunology, Utrecht, the Netherlands.
Robert-Jan LebbinkVirology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands.
Jeffrey M BeekmanDepartment of Pediatric Pulmonology, Wilhelmina Children's Hospital, University Medical Center, Utrecht University, Utrecht, the Netherlands.
Monique NijhuisVirology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands.
Annemarie M J WensingVirology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands.
University Medical Center Utrecht · NLWilhelmina Children's Hospital · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 infection after coronavirus disease 2019 vaccination raises concerns about the emergence of vaccine escape variants. Here we characterize 14 breakthrough infections among 5860 fully vaccinated Dutch health care workers ≥14 days after the final dose of vaccination with either BNT162b2, mRNA-1273, or Ad26.COV2.S. These breakthrough infections presented with regular B.1.1.7 (Alpha) and B.1.617.2 (Delta) variants and high viral loads, despite normal vaccine-induced B- and T-cell immune responses detected by live virus neutralization assays and ELISpot. High-risk exposure settings, such as in households, indicate a potential risk of viral transmission despite full vaccination.

Indexed as

COVID-19immunitypostvaccination infectionSARS-CoV-2vaccine breakthrough

Identifiers

PMID34988250
PMCPMC8714358
OpenAlexW3212440415

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.